Kisqali (600 MG Dose) and Piqray
Determining the interaction of Kisqali (600 MG Dose) and Piqray and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration of inhibitors of the breast cancer resistance protein (BCRP) transporter with alpelisib may increase the plasma concentrations and risk of adverse effects of alpelisib, which is a substrate of this efflux transporter. Alpelisib has been identified as a substrate of BCRP in in vitro studies. However, clinical data are not available. MANAGEMENT: According to the manufacturer, concomitant use of alpelisib with BCRP inhibitors should be avoided. If coadministration is required, patients should be closely monitored for alpelisib-related adverse reactions, including hyperglycemia, diarrhea, rash, acute kidney injury, abdominal pain, and anemia. References "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Professional:GENERALLY AVOID: Coadministration of inhibitors of the breast cancer resistance protein (BCRP) transporter with alpelisib may increase the plasma concentrations and risk of adverse effects of alpelisib, which is a substrate of this efflux transporter. Alpelisib has been identified as a substrate of BCRP in in vitro studies. However, clinical data are not available.
MANAGEMENT: According to the manufacturer, concomitant use of alpelisib with BCRP inhibitors should be avoided. If coadministration is required, patients should be closely monitored for alpelisib-related adverse reactions, including hyperglycemia, diarrhea, rash, acute kidney injury, abdominal pain, and anemia.
- "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: ribociclib
Brand name: Kisqali
Synonyms: Kisqali
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Kisqali (600 MG Dose)-Piqray 200MG Daily Dose
- Kisqali (600 MG Dose)-Piqray 250MG Daily Dose
- Kisqali (600 MG Dose)-Piqray 300MG Daily Dose
- Kisqali (600 MG Dose)-Pirbuterol Inhalation
- Kisqali (600 MG Dose)-Pirfenidone
- Kisqali (600 MG Dose)-Pirmella 1/35
- Piqray-Kisqali Femara Co-Pack
- Piqray-Kisqali Femara Co-Pack 200 mg-2.5 mg Dose
- Piqray-Kisqali Femara Co-Pack 400 mg-2.5 mg Dose
- Piqray-Kisqali Femara Co-Pack 600 mg-2.5 mg Dose
- Piqray-Kitabis Pak
- Piqray-Kitabis Pak inhalation